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 Despite the many advances made in understanding the manifestations and conse-
quences of hyponatremia, and the availability of effective pharmacologic therapies for 
the treatment of hyponatremia, it is obvious that we do not yet have a uniformly ac-
cepted consensus on how and when this disorder should be treated. To achieve this 
consensus, additional translational and clinical research will be necessary to establish 
the knowledge base upon which evidence-based recommendations can be made with 
confidence. 
 Basic/Translational Studies That Have High Priority 
 Mechanisms Responsible for Bone Loss with Chronic Hyponatremia 
 Published studies now provide compelling evidence that osteoclasts directly sense and 
respond to low [Na + ]. Likely, this serves to liberate stored sodium from bone, and thus 
represents an adaptation to mitigate the effects of sodium deficiency on brain, heart, 
testis, and likely other organs. The molecular mechanisms underlying this response 
represents an exciting target for future investigation, with the promise of uncovering 
a potential low [Na + ] sensing receptor or sodium channel on the plasma membrane 
of osteoclasts, along with the associated downstream activated signaling pathways. 
 Mechanisms Responsible for Gait Instability and Falls with Chronic Hyponatremia 
 Studies in both humans and experimental animals have documented gait disturbanc-
es that are likely responsible for the increased rate of falls in hyponatremic patients, 
and more recent studies have found decreased nerve conduction velocity. Whether 
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these are manifestations of the decreased brain osmolyte levels, including important 
excitatory motor neurotransmitters such as glutamate, or other neurophysiological 
changes, remains to be ascertained. As well, whether the gait instability is completely 
reversible after correction of chronic hyponatremia, as suggested by short-term stud-
ies in humans and animals, remains to be determined. 
Effects of Hyponatremia on Malignant Cells
It is becoming more and more evident that hyponatremia negatively affects the prog-
nosis of cancer patients, both with and without metastatic disease. Although this as-
sociation with worse outcomes has been documented in multiple clinical studies, the 
potential mechanisms through which this might occur are not understood. In vitro 
and in vivo studies on the effects of low sodium concentrations on malignant cell pro-
liferation, invasiveness, and alterations of signaling pathways would be illuminating 
in order to better understand this strong association.
 Effects of Chronic Hyponatremia on other Body Organs 
 Although significant progress has been made in understanding the effects of hypona-
tremia on the brain and bone, it is apparent that other organs are affected as well. Aged 
male hyponatremic rats have hypogonadism, as indicated by marked decrease of tes-
ticular weight and abnormal testicular histology, decreased body fat, skeletal muscle 
sarcopenia by densitometry, and cardiomyopathy, manifested as increased heart weight 
per body weight, histomorphometric evidence of reduced myocyte number, and marked 
perivascular and interstitial fibrosis. The functional consequences of these findings re-
main to be studied, as well as the intriguing hypothesis that hyponatremia may exacer-
bate multiple manifestations of senescence thereby speeding the aging process. 
 Clinical Research Studies That Have High Priority 
 Improvement of Symptomatic Hyponatremia 
 Although it is clear that correction of hyponatremia can improve many of the neu-
rological symptoms associated with hyponatremia and is life-saving in cases with 
severe neurological symptomatology, assessment of symptomatic improvement of 
the more subtle neurocognitive symptoms associated with milder degrees of hypo-
natremia is challenging. This is further complicated by the fact that these symptoms 
often occur in older patients with varying degrees of baseline dementia and in pa-
tients with other comorbidities such as heart failure, cirrhosis, pulmonary disease, 
cancer, and psychiatric disease that can also cause neurocognitive impairments. 
Assessment of neurocognitive deficits and improvements with correction of hypo-
natremia is essential if we are to develop scientifically valid guidelines to identify 
which patients will benefit from active treatment of both acute and chronic hypo-
natremia. 
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 Improvement of Clinical Outcomes 
 The strong independent association of hyponatremia with a variety of adverse clinical 
outcomes makes randomized controlled trials of the impact of more effective treat-
ment of hyponatremia in hospitalized patients a high priority for the many diseases 
in which hyponatremia is known to be associated with adverse outcomes. Hyponatre-
mia has a strong and independent association with a variety of serious adverse clinical 
outcomes, such as hospitalization rate and mortality. This makes randomized con-
trolled trials of the impact of more effective treatment of chronic hyponatremia a high 
priority for the many diseases in which chronic hyponatremia is strongly associated 
with adverse outcomes. 
 Effectiveness and Safety of Different Treatments for Hyponatremia 
 The indications for the use of vasopressin receptor antagonists by regulatory agencies 
differ substantially worldwide, and various treatment guidelines published to date 
also differ substantially in regard to appropriate hyponatremia management, includ-
ing recommendations of therapies with inadequate evidence databases. There are 
many reasons for this failure to achieve consensus, but primarily it is the lack of pro-
spective controlled studies comparing different treatments in various groups of pa-
tients. 
 Prevention of Falls, Osteoporosis, and Fractures 
 The strong association of hyponatremia with increased fracture rates as inde-
pendently documented in diverse geographic areas has established hyponatre-
mia as a previously unrecognized risk factor for fractures. Although this asso-
ciation is clear and the mechanisms whereby hyponatremia could increase the 
risk of falls and fractures is becoming known, whether treatment of chronic 
hyponatremia with more effective therapies can improve bone health and re-
duce falls and fracture rates, particularly in older patients, remains to be studied 
prospectively. 
Improvement of Quality of Life 
It is clear that the potential benfits of treating hyponatremia cannot be assessed ade-
quately simply by measures of improvements in mortality. It is equally important 
from a clinical perspective to assess quality of life measures, particularly in older pa-
tients who have the highest incidence of hyponatremia as well as the greatest burden 
of co-morbidities. Multiple studies have suggested improvement of a variety of pa-
tient-reported symptoms following improvements in the serum sodium concentra-
tion of hyponatremic patients, but larger studies using better defined instruments to 
evaluate the known symptoms associated with chronic hyponatremia would provide 
valuable input with regard to indications to treat relatively asymptomatic patients 
with chronic hyponatremia.
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 Reduction of Hospital Resource Utilization 
 Given the substantial economic burden associated with hyponatremia, whether more 
effective treatment of hyponatremia can reduce the increased costs that have been 
found to be associated with hyponatremia is a crucial question. This is particularly 
important for assessing the cost-benefit ratio of new therapies for hyponatremia, such 
as the vaptans, in view of their high costs. 
 Conclusions 
 Until the above questions can be answered via additional high quality translational 
and clinical research studies, physicians must recognize the primary role that clinical 
judgment must continue to play in making decisions about the management of hypo-
natremia in individual patients. Their recommendations should take into account ap-
propriate appraisals of evidence by authoritative experts in the field, the decisions of 
regulatory agencies based on critical reviews of the efficacy and safety data for ap-
proved treatments for hyponatremia and, most importantly, the specialized needs of 
individual hyponatremic patients. 
 However, the future of hyponatremia research is bright. Scientific disciplines and 
funding agencies are beginning to appreciate the magnitude of the clinical and eco-
nomic burden of hyponatremia, and are no longer relegating low sodium levels to the 
category of a “clinically insignificant” laboratory abnormality. Recognition that an 
absence of clinical symptoms does not mean that a metabolic disorder is not having 
significant adverse effects on body organs and functions, as has been long recognized 
for other metabolic disorders such as diabetes and hypertension, will inevitably lead 
to a re-assessment of appropriate treatment recommendations for chronic hypona-
tremia, even when mild and minimally symptomatic. There is every reason to believe 
that the steady increase in hyponatremia publications shown in Figure 1 (in the 
 Introduction, pp 1–7) will continue into the foreseeable future, and with that will 
come a fuller and richer understanding of the many ways in which hyponatremia af-
fects the human body, many of which we likely are not even aware of at the present 
time. The editors look forward eagerly to the next two decades of research and the 
knowledge that it will bring to scientists and clinicians everywhere. 
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